Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 122-127

  Nishiyama, Tomoki ^a  

^a National Hospital Organization   (Japan)

Author keywords

Cytokine; Endotoxin shock; Lung injury; Serotonin (5 HT)2A receptor

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; HEMODYNAMICS; LUNG INJURY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE RATE; RAT; SEPTIC SHOCK; SURVIVAL RATE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HEMODYNAMICS; LUNG; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RESPIRATION; SHOCK, SEPTIC; SUCCINATES; SURVIVAL RATE;

EID: 67349253006     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.041     Document Type: Article

References (35)

1. Aderka D., Le J., and Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells and in mice. J. Immunol. 143 (1989) 3517-3523
2. Berkow R.L., and Dodson M.R. Biochemical mechanisms involved in the priming of neutrophils by tumor necrosis factor. J. Leuk. Biol. 44 (1988) 345-352
3. Cannon J.G., Tompkins R.G., Gelfand J.A., Michie H.R., Stanford G.G., van der Meer J.W.M., Endres S., Lennemann G., Corsetti J., Chernow B., Wilmore D.W., Wolff S.M., Burke J.F., and Dinarello C.A. Circulating interleukin-1 and tumor necrosis factor levels in septic shock and experimental endotoxin fever. J. Infect. Disord. 161 (1990) 79-84
4. Casey L.C., Balk R.A., and Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119 (1993) 771-778
5. Cassatella M.A., Meda L., Bonora S., Ceska M., and Constantin G. Interleukin 10 (IL-10) inhibits the release of pro-inflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med. 178 (1993) 2207-2211
6. 2A receptors. Int. Immunol. 15 (2003) 233-240
7. Faust S.N., Heyderman R.S., and Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit. Care Med. 29 (2001) S62-S68
8. Foon K.A., Wahl S.M., Oppenheim J.J., and Rosenstreich D.L. Serotonin-induced production of a monocyte chemotactic factor by human peripheral blood leukocytes. J. Immunol. 117 (1976) 1545-1552
9. Frishman W.H., Huberfeld S., Okin S., Wang Y.H., Kumar A., and Shareef B. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J. Clin. Pharmacol. 35 (1995) 541-572
10. Gennari R., Alexander J.W., Pyles T., Hartmann S., and Ogle C.K. Effects of antimurine interleukin-6 on bacterial translocation during gut-derived sepsis. Arch. Surg. 129 (1994) 1191-1197
11. Graziano F.M., Cook E.B., and Stahl J.L. Cytokines, chemokines, RANTES, and eotaxin. Allergy Asthma Proc. 20 (1999) 141-146
12. Israilova M., Suzuki F., Tanaka T., Nagatomo T., Taniguchi T., and Muramatsu I. Binding and functional affinity of sarpogrelate, its metabolite M-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology 65 (2001) 69-73
13. Ito T., Ikeda U., Shimpo M., Yamamoto K., and Shinoda K. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation 102 (2000) 2522-2527
14. Komatsu T., Enjouji S., Nakai H., Inokuchi T., and Iida S. Studies on the metabolic fate of (±)-2-(Dimethylamino)-1-[[ο-(m-methoxyphenethyl)-phenoxy]methyl]ethyl hydrogen siccinate hydrochloride (MCI-9042) (II): absorption, distribution, metabolism and excretion after a single administration to rats. Yakubutsu Dotai (in Japanese with English abstract) 6 (1991) 377-398
15. Levi M. Platelets in sepsis. Hematology 10 (2005) S129-S131
16. Libert C., Vink A., Coulie P., Brouckaert P., Everaerdt B., Snick J.V., and Fiers W. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur. J. Immunol. 22 (1992) 2625-2630
17. Macarthur H., Couri D.M., Wilken G.H., Westfall T.C., Lechner A.J., Matuschak G.M., Chen Z., and Salvemini D. Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit. Care Med. 31 (2003) 237-245
18. Maruyama K., Kinami J., Sugita Y., Takada Y., Sugiyama E., Tsuchihashi H., and Nagatomo T. MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. J. Pharmacobio-Dyn. 14 (1991) 177-181
19. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., Cerami A., Wolff S.M., and Wilmore D.W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318 (1988) 1481-1486
20. 2A serotonin receptor. J. Pharmacol. Sci. 102 (2006) 55-63
21. Nishihara K., Yamashita A., Tanaka N., Kawamoto R., Imamura T., Yamamoto R., Eto T., and Asada Y. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J. Thromb. Haemostat. 4 (2006) 247-255
22. Pallua N., and Heimburg v.D. Pathogenic role of interleukin-6 in the development of sepsis. Part I: study in a standardized contact burn murine model. Crit. Care Med. 31 (2003) 1490-1494
23. 2C receptor subtypes by molecular modeling. Life Sci. 73 (2003) 193-207
24. Selzman C.H., Shames B.D., Miller S.A., Pulido E.J., Meng X., McIntyre Jr. R.C., and Harken A.H. Therapeutic implications of interleukin-10 in surgical disease. Shock 10 (1998) 309-318
25. Sibbald W., Peters S., and Lindsay R.M. Serotonin and pulmonary hypertension in human septic ARDS. Crit. Care Med. 8 (1980) 490-494
26. 2 serotonergic receptor antagonists. J. Immunol. 137 (1986) 76-282
27. Taniguchi T., Kanakura H., Takemoto Y., and Yamamoto K. Evaluation of the animal model for endotoxin-induced shock. Masui (Jpn. J. Anesthesiol) 52 (2003) 656-661
28. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., and Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83 (1994) 113-118
29. Timmons S., Huzoor-Akbar, Grabarek J., Marek K., and Jacek H. Mechanism of human platelet activation by endotoxic glycolipid-bearing mutant Re595 of Salmonella Minnesota. Blood 68 (1986) 1015-1023
30. 2A antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc. Dis. 24 (2007) 264-270
31. Vannier E., Miller L.C., and Dinarello C.A. Coordinated anti-inflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc. Natl. Acad. Sci. USA 89 (1992) 4076-4080
32. Van Nueten J.M., Leysen J.E., De Clerck F., and Vanhoutte P.M. Serotonergic receptor subtypes and vascular reactivity. J. Cardiovasc. Pharmacol. 6 (1984) S564-S574
33. Walther A., Yilmaz N., Schmidt W., Bach A., Gebhard M.M., Martin E., and Schmidt H. Methysergide attenuates leukocyte-independent plasma extravasation during endotoxemia. J.Crit. Care 16 (2001) 121-126
34. Walther A., Petri E., Peter C., Czabanka M., and Martin E. Selective serotonin-receptor antagonism and microcirculatory alterations during experimental endotoxemia. J. Surg. Res. 143 (2007) 216-223
35. Zivot J.B., and Hoffman W.D. Pathogenic effects of endotoxin. New Horiz. 3 (1995) 267-275